Acadia’s Alzheimer’s Psychosis Drug Missed Its Main Goal. Phase 3 Continues Anyway.

Acadia’s remlifanserin narrowly missed its Phase 2 primary endpoint in Alzheimer’s psychosis. Safety remained favorable, Phase 3 is continuing, and the stock sold off first.